T. Rowe Price reports 1.89M ADRs (3.7%) in Immunocore

T. Rowe Price Investment Management, Inc. filed an amendment to a Schedule 13G reporting beneficial ownership of 1,891,600 ADRs of Immunocore Holdings plc, representing 3.7% of the class.

Rhea-AI Filing Summary

T. Rowe Price Investment Management, Inc. filed an amendment to a Schedule 13G reporting beneficial ownership of 1,891,600 ADRs of Immunocore Holdings plc, representing 3.7% of the class. The filing lists sole voting and dispositive power over the reported shares and includes a signed declaration dated 05/15/2026.

The filing affirms ownership is 5% or less and contains a customary denial that the filer is the beneficial owner. No transaction details or purchase/sale directions are reported in this excerpt.

Insights

Institutional Ownership Analyst

Large asset manager reports a passive stake below the 5% reporting threshold.

The amendment lists 1,891,600 ADRs (3.7%) with sole voting and dispositive power, consistent with an institutional position reported on Schedule 13G. The filing's language and the 5% or less statement indicate passive investment status rather than an active control intent.

Holder decisions will determine future disclosure; subsequent amendments would appear if ownership crosses regulatory thresholds or the filer changes intent.

Key Figures

Beneficial ownership: 1,891,600 ADRs Percent of class: 3.7% Signature date: 05/15/2026

3 metrics

Beneficial ownership 1,891,600 ADRs Amount beneficially owned as reported in Item 4(a)

Percent of class 3.7% Percent of class reported in Item 4(b)

Signature date 05/15/2026 Signed declaration date at the end of the filing

Key Terms

Schedule 13G/A, beneficial ownership, sole dispositive power

3 terms

Schedule 13G/A regulatory

"amendment to a Schedule 13G reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership financial

"Amount beneficially owned: 1891600 (b) Percent of class: 3.7 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole dispositive power regulatory

"Sole Dispositive Power 1,891,600.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does T. Rowe Price report in IMCR?

T. Rowe Price reports beneficial ownership of 1,891,600 ADRs, equal to 3.7% of Immunocore Holdings plc's ADR class, as stated in the amendment filed and signed on 05/15/2026. The filing lists sole voting and dispositive power over these ADRs.

Does this Schedule 13G/A indicate active control of Immunocore?

No. The filing is an amendment on Schedule 13G and states ownership of 5% or less, which is consistent with a passive investor reporting status rather than an intent to exert control or influence over corporate governance.

What voting and disposition powers does T. Rowe Price report?

The amendment states sole voting power for 1,891,600 ADRs and sole dispositive power for the same number, with 0 shared voting or dispositive power listed in the filing's ownership table.

When was the Schedule 13G/A amendment signed?

The amendment bears a signature dated 05/15/2026, signed by Ellen York as Vice President for T. Rowe Price Investment Management, Inc., per the closing signature block in the provided excerpt.

Will future transactions require updated disclosures by T. Rowe Price?

If the holder's classification or ownership threshold changes, subsequent amendments would be required. The filing here reflects passive ownership at 3.7%; any increase above reportable thresholds or change in intent must be disclosed in later filings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 10:06 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

IMMUNOCORE HOLDINGS PLC-ADR

(Name of Issuer)

ADR

(Title of Class of Securities)

45258D105

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 45258D105

1

Names of Reporting Persons

T. Rowe Price Investment Management, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,891,600.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,891,600.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,891,600.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IMMUNOCORE HOLDINGS PLC-ADR
(b)	Address of issuer's principal executive offices: 90 PARK DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE, X0, OX14 4RY
Item 2.
(a)	Name of person filing: T. Rowe Price Investment Management, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: ADR
(e)	CUSIP No.: 45258D105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1891600
(b)	Percent of class: 3.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1891600
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1891600
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Investment Management, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026